Quality-of-life concerns in lung cancer patients

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 6, 2010, Pages 667-676

  Siddiqui, Farzan ^a   Konski, Andre A ^b   Movsas, Benjamin ^a  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

health related quality of life; lung cancer; quality adjusted life year

Indexed keywords

AMIFOSTINE; CARBOPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PEMETREXED;

ALOPECIA; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METHODOLOGY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 78650439464     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.81     Document Type: Review

References (90)

1. Fayers PM. Quality of Life: Assessment, Analysis and Interpretation. Wiley, Chichester, UK (2000).
2. Leplege A, Hunt S. The problem of quality of life in medicine. JAMA 278(1), 47-50 (1997).
3. Quality of Life Assessment. The WHOQoL Group, 1994. What quality of life? The WHOQoL Group. In: World Health Forum. WHO, Geneva, Switzerland 6 (1996).
4. Garcia SF, Cella D, Clauser SB et al. Standardizing patient-reported outcomes 7 assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J. Clin. Oncol. 25(32), 5106-5112 (2007).
5. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J. Natl Cancer Inst. 81(7), 485-495 (1989).
6. Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N. Engl J. Med. 334(13), 835-840 (1996).
7. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J. Clin. Epidemiol. 53(5), 459-468 (2000).
8. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12(3), 199-220 (1995).
9. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J. Clin. Oncol. 15(3), 974-986 (1997). (Pubitemid 27106280)
10. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5), 1151-1161 (1995).
11. Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual. Life Res. 8(3), 181-195 (1999).
12. List MA, D'Antonio LL, Cella DF et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 77(11), 2294-2301 (1996).
13. Heffernan N, Cella D, Webster K et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire. J. Clin. Oncol. 20(9), 2229-2239 (2002).
14. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J. Clin. Oncol. 19(6), 1809-1817 (2001).
15. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50(6), 920-928 (1997).
16. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365-376 (1993).
17. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur. J. Cancer 30A(5), 635-642 (1994).
18. Nicklasson M, Bergman B. Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Qual. Life Res. 16(6), 1019-1028 (2007).
19. Hollen PJ, Gralla RJ, Kris MG et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73(8), 2087-2098 (1994).
20. Stewart AL, Ware J E. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Duke University Press, Durham, UK (1992).
21. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
22. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 32(1), 40-66 (1994).
23. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31(3), 247-263 (1993).
24. Osoba D. Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat. Rev. 22(Suppl. A), 69-73 (1996).
25. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49(2), 227-230 (2001).
26. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur. J. Cancer 33(7), 1025-1030 (1997).
27. Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual. Life Res. 6(2), 151-158 (1997).
28. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur. J. Cancer 37(3), 332-339 (2001).
29. Efficace F, Bottomley A. Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer. J. Clin. Oncol. 23(6), 1335-1336 (2005); author reply: 23(6), 1336 (2005).
30. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31(2-3), 233-240 (2001).
31. Siddiqui F, Kachnic LA, Movsas B. Quality-of-life outcomes in oncology. Hematol. Oncol. Clin. North Am. 20(1), 165-185 (2006).
32. Moinpour CM, Sawyers Triplett J, McKnight B et al. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology 9(4), 340-354 (2000).
33. Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat. Med. 16(11), 1197-1209 (1997).
34. Troxel AB, Fairclough DL, Curran D, Hahn EA. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat. Med. 17(5-7), 653-666 (1998). (Pubitemid 28118937)
35. Curran D, Molenberghs G, Fayers PM, Machin D. Incomplete quality of life data in randomized trials: missing forms. Stat. Med. 17(5-7), 697-709 (1998). (Pubitemid 28118940)
36. Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat. Med. 17(5-7), 679-696 (1998). (Pubitemid 28118939)
37. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127(8 Pt 2), 757-763 (1997).
38. Little RJ, Rubin DB. Statistical Analysis with Missing Data. Wiley, NJ, USA (2002).
39. Sales AE, Plomondon ME, Magid DJ, Spertus JA, Rumsfeld JS. Assessing response bias from missing quality of life data: the Heckman method. Health Qual. Life Outcomes 2, 49 (2004).
40. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin. Proc. 77(4), 371-383 (2002).
41. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16(1), 139-144 (1998).
42. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol. 17(6), 1654-1663 (1999). (Pubitemid 29269233)
43. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18(7), 1481-1491 (2000).
44. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur. J. Cancer 36(14), 1788-1795 (2000). (Pubitemid 30639499)
45. Goldstein RS, Gort EH, Guyatt GH, Feeny D. Economic analysis of respiratory rehabilitation. Chest 112(2), 370-379 (1997).
46. Ware JE, Gandek B, Keller SD; the IQoLA Project Group. Evaluating instruments used cross-nationally: methods from the IQoLA Project. In: (Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition). Spilker B (Ed.). Raven Press, NY, USA 681-692 (1996).
47. Movsas B. Quality of life in oncology trials: a clinical guide. Semin. Radiat. Oncol. 13(3), 235-247 (2003).
48. Cohen J. Statistical Power Analysis for the Behavioral Sciences (L Erlbaum Associates, NJ, USA (1988).
49. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med. Care 37(5), 469-478 (1999).
50. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J. Clin. Epidemiol. 52(9), 861-873 (1999).
51. Wyrwich KW, Tierney WM, Wolinsky FD. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. Qual. Life Res. 11(1), 1-7 (2002).
52. Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J. Clin. Epidemiol. 57(9), 898-910 (2004).
53. Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 8(2), 117-127 (2005).
54. Langendijk JA, Aaronson NK, de Jong JM et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J. Clin. Oncol. 19(8), 2123-2133 (2001).
55. Sundstrom S, Bremnes R, Aasebo U et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national Phase III trial. J. Clin. Oncol. 22(5), 801-810 (2004).
56. Erridge SC, Gaze MN, Price A et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin. Oncol. (R Coll. Radiol.) 17(1), 61-67 (2005).
57. Bezjak A, Dixon P, Brundage M et al. Randomized Phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int. J. Radiat. Oncol. Biol. Phys. 54(3), 719-728 (2002).
58. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother. Oncol. 55(1), 19-25 (2000).
59. Efficace F, Bottomley A, Smit EF et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann. Oncol. 17(11), 1698-1704 (2006).
60. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12), 3131-3135 (1991).
61. Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85(2), 333-340 (1999).
62. Brown J, Thorpe H, Napp V et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J. Clin. Oncol. 23(30), 7417-7427 (2005).
63. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J. Clin. Oncol. 21(8), 1536-1543 (2003).
64. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J. Clin. Oncol. 23(28), 6865-6872 (2005).
65. Movsas B, Moughan J, Sarna L et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J. Clin. Oncol. 27(34), 5816-5822 (2009).
66. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br. J. Cancer 83(4), 447-453 (2000).
67. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27(3), 145-157 (2000).
68. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl Cancer Inst. 91(1), 66-72 (1999).
69. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised Phase III trial. Joint Lung Cancer Study Group. Eur. J. Cancer 34(7), 1036-1044 (1998).
70. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24(1), 17-24 (1999).
71. Detmar SB, Aaronson NK, Wever LD, Muller M, Schornagel JH. How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J. Clin. Oncol. 18(18), 3295-3301 (2000).
72. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 288(23), 3027-3034 (2002).
73. Velikova G, Booth L, Smith AB et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J. Clin. Oncol. 22(4), 714-724 (2004).
74. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146(4), 473-481 (1992).
75. Gold MR. Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
76. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005).
77. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61(3), 405-415 (2008).
78. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20-27 (2009).
79. Barbera L, Walker H, Foroudi F, Tyldesley S, Mackillop W. Estimating the benefit and cost of radiotherapy for lung cancer. Int. J. Technol. Assess. Health Care 20(4), 545-551 (2004).
80. van den Hout WB, Kramer GW, Noordijk EM, Leer JW. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J. Natl Cancer Inst. 98(24), 1786-1794 (2006).
81. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Bio-metrics 45(3), 781-795 (1989).
82. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat. Med. 9(11), 1259-1276 (1990).
83. Bonner JA, Sloan JA, Shanahan TG et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J. Clin. Oncol. 17(9), 2681-2691 (1999).
84. Sloan JA, Bonner JA, Hillman SL et al. A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). Int. J. Radiat. Oncol. Biol. Phys. 52(2), 371-381 (2002).
85. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005). (Pubitemid 41007845)
86. Kassam F, Shepherd FA, Johnston M et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J. Thorac. Oncol. 2(1), 39-43 (2007).
87. Revicki DA, Feeny D, Hunt TL, Cole BF. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual. Life Res. 15(3), 411-423 (2006).
88. Functional Assessment of Chronic Illness Therapy www.facit.org
89. Phillips C. What is QALY? (2009) www.nice.org.uk/media/C18/30/ SVJ2PUBLICATION2008.pdf
90. EQ-5D™ www.euroqol.org/home.html